Muzaffar Qazilbash, MD
Enriched profileProfessor, Department of Stem Cell Transplantation and Cellular Therapy · The University of Texas MD Anderson Cancer Center
Muzaffar Qazilbash is Professor, Department of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 873 publications with 13,027 citations (h-index 54); ClinicalTrials.gov lists 12 registered studies with this person as an investigator.
Data verified 10 Oct 2026
Overview
Updated 16 Oct 2026
Muzaffar Qazilbash, M.D., is Professor, Department of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center. The public record shows 873 publications with 13,027 citations (h-index 54), centered on Hematopoietic Stem Cell Transplantation, Multiple Myeloma Research and Treatments, Lymphoma Diagnosis and Treatment. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 4 companies.
- Most recent indexed publication: 2026 · Blood cancer journal
- Top research focus: Hematopoietic Stem Cell Transplantation
- 12 registered trials on ClinicalTrials.gov
- Open Payments reporting from 4 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 53 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 228.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:
- Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma
Sponsor: M.D. Anderson Cancer Center
- Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
Sponsor: M.D. Anderson Cancer Center
- Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant
Sponsor: M.D. Anderson Cancer Center
Industry payments
Updated 16 Oct 2026
4 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Celgene CorporationProgram year20251 payment
- GENZYME CORPORATIONProgram year20243 payments
- E.R. Squibb & Sons, L.L.C.Program year20241 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
39.1%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor18.8%Valacyclovir100%Part D≥14 patientsAzole Antifungal12.3%Posaconazole100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
30.4%Thalidomide Analog30.4%Revlimid100%Part D<11 patientsMetabolism & gastrointestinal
19.6%Bile Acid10.9%Ursodiol100%Part D<11 patientsProton pump inhibitor8.7%Pantoprazole Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 16 Oct 2026
148 congress contributions (2005–2026) across AACR, ASCO, ASH, ASTRO per OpenAlex. The most recent:
- A phase II trial of tagraxofusp, hyper-CVAD, and venetoclax for patients with newly diagnosed or relapsed/refractory BPDCN.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Autologous stem cell transplantation for AL amyloidosis: a multicenter summary of outcomes 2010-2020.
Bone marrow transplantation
Article2026 - Donor-specific HLA mismatch: haploidentical versus 7/8 mismatched unrelated donor hematopoietic cell transplantation with PTCy.
Bone marrow transplantation
Letter2026
Most-cited works
by citation count (OpenAlex)- 01Lenalidomide after Stem-Cell Transplantation for Multiple MyelomaArticle1,157 citations2012
- 02
- 03Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cellsArticle501 citations2016
- 04Cord-Blood Engraftment with Ex Vivo Mesenchymal-Cell CocultureArticle475 citations2012
- 05
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/muzaffar-qazilbash-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Doximity
opmed.doximity.com/authors/muzaffar-h-qazilbash-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →opmed.doximity.com ↗ - LinkedIn
linkedin.com/in/muzaffar-qazilbash-3a377b30a
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - LinkedIn
linkedin.com/in/muzaffar-qazilbash-424b246
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Other
healthtree.org/myeloma/podcasts/combining-myeloma-vaccines-and-t-cell
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthtree.org ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
S Rajkumar, MD
Mayo Clinic
Meletios Dimopoulos, MD
National and Kapodistrian University of Athens